Pub Date : 2024-01-01Epub Date: 2024-09-13DOI: 10.1080/17581869.2024.2400992
Alice L Ye, Sudhakar Tummala, Suchi Shah, Ravi Tummala, Robert Y North, Mazen Zein
Aim: Chronic shoulder pain due to iatrogenic spinal accessory nerve (SAN) injury continues to be under-recognized, resulting in delayed time-to-diagnosis and poorer outcomes. Solutions are needed to improve the management of this condition, which can be challenging as care needs to be coordinated across pain management, neurophysiology, rehabilitation and reconstructive surgery.Cases: We present a series of six patients with shoulder pain refractory to conservative pain treatments to highlight how SAN injuries continued to be missed and treatment delayed, even at advanced care centers. The time to diagnosis of SAN palsy took an average of 21 months and treatment was inconsistent for all patients.Discussion: None of the six cases had initial suspicion of SAN palsy and only one patient received targeted SAN injury care. SAN treatment should be started as early as possible so that patients can be referred for prompt surgical evaluation if they fail conservative management. Integrated care pathways may be a solution for formalizing multidisciplinary team involvement and improving SAN injury outcomes.Conclusion: Systemic processes, such as integrated care pathways, are needed to optimize early recognition and targeted treatment of SAN injury and may be beneficial for other underdiagnosed and undertreated neuropathic pain conditions.
目的:由于先天性脊髓附属神经(SAN)损伤引起的慢性肩痛仍未得到充分认识,导致诊断时间延迟和治疗效果不佳。由于需要协调疼痛管理、神经生理学、康复和重建手术等方面的治疗,因此改善这种病症的管理非常具有挑战性:我们介绍了一组六名肩痛患者的病例,这些患者对保守的疼痛治疗无效,这突显了即使在先进的医疗中心,SAN损伤仍会被漏诊和延误治疗。所有患者确诊SAN麻痹的时间平均为21个月,治疗方法也不一致:讨论:六个病例中没有一个最初怀疑有SAN麻痹,只有一名患者接受了有针对性的SAN损伤治疗。应尽早开始 SAN 治疗,以便在保守治疗失败后及时转诊进行手术评估。综合护理路径可能是使多学科团队参与正规化并改善SAN损伤预后的一种解决方案:结论:综合护理路径等系统流程可优化对 SAN 损伤的早期识别和针对性治疗,对其他诊断不足和治疗不足的神经病理性疼痛病症也大有裨益。
{"title":"Chronic shoulder pain due to spinal accessory nerve palsies present opportunities for improved care integration.","authors":"Alice L Ye, Sudhakar Tummala, Suchi Shah, Ravi Tummala, Robert Y North, Mazen Zein","doi":"10.1080/17581869.2024.2400992","DOIUrl":"10.1080/17581869.2024.2400992","url":null,"abstract":"<p><p><b>Aim:</b> Chronic shoulder pain due to iatrogenic spinal accessory nerve (SAN) injury continues to be under-recognized, resulting in delayed time-to-diagnosis and poorer outcomes. Solutions are needed to improve the management of this condition, which can be challenging as care needs to be coordinated across pain management, neurophysiology, rehabilitation and reconstructive surgery.<b>Cases:</b> We present a series of six patients with shoulder pain refractory to conservative pain treatments to highlight how SAN injuries continued to be missed and treatment delayed, even at advanced care centers. The time to diagnosis of SAN palsy took an average of 21 months and treatment was inconsistent for all patients.<b>Discussion:</b> None of the six cases had initial suspicion of SAN palsy and only one patient received targeted SAN injury care. SAN treatment should be started as early as possible so that patients can be referred for prompt surgical evaluation if they fail conservative management. Integrated care pathways may be a solution for formalizing multidisciplinary team involvement and improving SAN injury outcomes.<b>Conclusion:</b> Systemic processes, such as integrated care pathways, are needed to optimize early recognition and targeted treatment of SAN injury and may be beneficial for other underdiagnosed and undertreated neuropathic pain conditions.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-06-14DOI: 10.1080/17581869.2024.2360381
Nicholas Averell, Brandon Goodwin, Seungkyu Park, Seth Spicer, Margaret Wilson, Jessica Mitchell, Nichole Martinez, Meejan Palhang, Jaimy Jabon, Richard Jermyn
Aim: To investigate the analyze the relationship between concentration platelet-dose in platelet-rich plasma (PRP) injections and improvements in pain when treating lateral epicondylitis. Methods: A systematic review was conducted into five medical databases, exploring the difference in pain outcomes based on concentration of PRP. Results: Initial querying of the databases yielded 1408 articles with 20 articles ultimately included. There was no statistical significance between effect sizes of the two treatment groups (high and low platelet concentration; p = 0.976). Conclusion: Both large and small concentrations of platelets depict significant reduction in pain, however, between subgroups there was no significance. It can thus be concluded that concentration of platelets in PRP does not impact overall pain relief.
{"title":"The concentration of platelets in PRP does not affect pain outcomes in lateral epicondylitis: a systematic review and meta-analysis.","authors":"Nicholas Averell, Brandon Goodwin, Seungkyu Park, Seth Spicer, Margaret Wilson, Jessica Mitchell, Nichole Martinez, Meejan Palhang, Jaimy Jabon, Richard Jermyn","doi":"10.1080/17581869.2024.2360381","DOIUrl":"10.1080/17581869.2024.2360381","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the analyze the relationship between concentration platelet-dose in platelet-rich plasma (PRP) injections and improvements in pain when treating lateral epicondylitis. <b>Methods:</b> A systematic review was conducted into five medical databases, exploring the difference in pain outcomes based on concentration of PRP. <b>Results:</b> Initial querying of the databases yielded 1408 articles with 20 articles ultimately included. There was no statistical significance between effect sizes of the two treatment groups (high and low platelet concentration; p = 0.976). <b>Conclusion:</b> Both large and small concentrations of platelets depict significant reduction in pain, however, between subgroups there was no significance. It can thus be concluded that concentration of platelets in PRP does not impact overall pain relief.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-07-23DOI: 10.1080/17581869.2024.2371779
Ali Valimahomed, David Dickerson, Henry Vucetic, Joseph Rutledge, Claire A Zurn, Nathan D Crosby, Joseph W Boggs
Aim: This real-world analysis aims to quantify improvements in multiple health domains in patients who received 60-day peripheral nerve stimulation (PNS) for shoulder pain.Materials & methods: Patients reported percent pain relief and Patient Global Impression of Change in quality of life, physical function and sleep at the end of treatment (EOT), 3 months, and 6 months.Results: Of 768 patients, 80.7% were responders in at least one domain at EOT. In a subset who were followed up, a cumulative 75% continued to respond in at least one domain through 6 months (85% [n = 140/165] at 3 months and 88% [n = 53/60] at 6 months).Conclusion: 60-day PNS used for shoulder pain produced multi-dimensional improvements across health domains at EOT and through 6 months.
{"title":"Real-world evidence of durable multi-dimensional improvement after 60-day peripheral nerve stimulation treatment used for shoulder pain.","authors":"Ali Valimahomed, David Dickerson, Henry Vucetic, Joseph Rutledge, Claire A Zurn, Nathan D Crosby, Joseph W Boggs","doi":"10.1080/17581869.2024.2371779","DOIUrl":"10.1080/17581869.2024.2371779","url":null,"abstract":"<p><p><b>Aim:</b> This real-world analysis aims to quantify improvements in multiple health domains in patients who received 60-day peripheral nerve stimulation (PNS) for shoulder pain.<b>Materials & methods:</b> Patients reported percent pain relief and Patient Global Impression of Change in quality of life, physical function and sleep at the end of treatment (EOT), 3 months, and 6 months.<b>Results:</b> Of 768 patients, 80.7% were responders in at least one domain at EOT. In a subset who were followed up, a cumulative 75% continued to respond in at least one domain through 6 months (85% [n = 140/165] at 3 months and 88% [n = 53/60] at 6 months).<b>Conclusion:</b> 60-day PNS used for shoulder pain produced multi-dimensional improvements across health domains at EOT and through 6 months.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-01-08DOI: 10.2217/pmt-2023-0087
Michael Dakkak
Calcification of the medial collateral ligament is a rare cause of medial knee pain along with functional impairment. Most cases are asymptomatic but those that are symptomatic typically respond to conservative management. However, in those instances with persistent symptoms that desire further intervention but want to minimize the risks associated with surgery, we present a novel approach for calcium removal with an ultrasound-guided percutaneous needle tenotomy with TenJet™ as a reasonable treatment modality.
{"title":"Ultrasound-guided treatment of medial collateral ligament calcification of the knee with TenJet™: a case report.","authors":"Michael Dakkak","doi":"10.2217/pmt-2023-0087","DOIUrl":"10.2217/pmt-2023-0087","url":null,"abstract":"<p><p>Calcification of the medial collateral ligament is a rare cause of medial knee pain along with functional impairment. Most cases are asymptomatic but those that are symptomatic typically respond to conservative management. However, in those instances with persistent symptoms that desire further intervention but want to minimize the risks associated with surgery, we present a novel approach for calcium removal with an ultrasound-guided percutaneous needle tenotomy with TenJet™ as a reasonable treatment modality.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139378169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-09-13DOI: 10.1080/17581869.2024.2400970
Kristy A Fisher, Terrance C Jenkins, Vinita Singh, Rupeng Li, Yawar J Qadri
As spinal cord stimulation (SCS) becomes a staple of chronic pain management, the SCS industry must constantly evolve to ensure safety, convenience and enhanced efficacy. Beyond waveforms and size, MR-conditionality is a key differentiator sought out by physicians and patients when choosing SCS devices. Many common SCS complications, including lead migration, can affect the MR-conditionality. The authors reviewed literature published between 2015 and 2024 using PubMed and Google Scholar databases, as well as US FDA labels for magnetic resonance imaging and technical manuals with further confirmation from local representatives. Through extensive review of the literature and direct extraction from each SCS device company, the authors aimed to investigate the specific terms of MR-conditionality under various circumstances. This article provides a collective reference of the MR-conditionality of the currently available SCS devices under normal conditions, as well as with common failure modes, such as lead migration, lead fracture and battery detachment.
{"title":"MR-conditionality failure modes: a comparison across various spinal cord stimulators.","authors":"Kristy A Fisher, Terrance C Jenkins, Vinita Singh, Rupeng Li, Yawar J Qadri","doi":"10.1080/17581869.2024.2400970","DOIUrl":"10.1080/17581869.2024.2400970","url":null,"abstract":"<p><p>As spinal cord stimulation (SCS) becomes a staple of chronic pain management, the SCS industry must constantly evolve to ensure safety, convenience and enhanced efficacy. Beyond waveforms and size, MR-conditionality is a key differentiator sought out by physicians and patients when choosing SCS devices. Many common SCS complications, including lead migration, can affect the MR-conditionality. The authors reviewed literature published between 2015 and 2024 using PubMed and Google Scholar databases, as well as US FDA labels for magnetic resonance imaging and technical manuals with further confirmation from local representatives. Through extensive review of the literature and direct extraction from each SCS device company, the authors aimed to investigate the specific terms of MR-conditionality under various circumstances. This article provides a collective reference of the MR-conditionality of the currently available SCS devices under normal conditions, as well as with common failure modes, such as lead migration, lead fracture and battery detachment.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-12-01DOI: 10.2217/pmt-2023-0117
Jasmine Hagan
To our readers, welcome to the first issue of Volume 14 of Pain Management. 2023 marked a significant year for the journal, as we received an impact factor of 1.7 and increased the number of issues from 8 to 12. This foreword presents some of our content highlights from 2023, covering our top articles from the year and providing you with an insight into what to expect in the forthcoming year.
{"title":"Exploring new horizons in pain relief: introducing Volume 14 of <i>Pain Management</i>.","authors":"Jasmine Hagan","doi":"10.2217/pmt-2023-0117","DOIUrl":"10.2217/pmt-2023-0117","url":null,"abstract":"<p><p>To our readers, welcome to the first issue of Volume 14 of <i>Pain Management.</i> 2023 marked a significant year for the journal, as we received an impact factor of 1.7 and increased the number of issues from 8 to 12. This foreword presents some of our content highlights from 2023, covering our top articles from the year and providing you with an insight into what to expect in the forthcoming year.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138461620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2024-01-09DOI: 10.2217/pmt-2023-0055
Debora B Martineau, Marco Fornasini, Daniela Suárez, Mario Paz, Cinthia Valarezo, Enrique Loor, Marixa Guerrero, Manuel E Baldeon
Background: There are limited data on non-oncological high-impact chronic pain (HICP) in Ecuador; we report the epidemiological characteristics of HICP. Materials & methods: In this cross-sectional study, we included a random sample of adult individuals who had cell phones. Results & conclusion: The weighted prevalence of HICP was 9.0%: 12.3% for women and 5.6% for men (p = 0.001). HICP was more frequently localized in the lower back and affected the economically active population. Nonsteroidal anti-inflammatory drugs were more commonly used; however, 61% of patients indicated that the effectiveness of their management was low. Overall, HICP had a negative impact on daily life activities. The effectiveness of the current treatment was low and should include an integrated approach.
{"title":"Epidemiology of non-oncological high-impact chronic pain in Ecuadorian adults in 2022.","authors":"Debora B Martineau, Marco Fornasini, Daniela Suárez, Mario Paz, Cinthia Valarezo, Enrique Loor, Marixa Guerrero, Manuel E Baldeon","doi":"10.2217/pmt-2023-0055","DOIUrl":"10.2217/pmt-2023-0055","url":null,"abstract":"<p><p><b>Background:</b> There are limited data on non-oncological high-impact chronic pain (HICP) in Ecuador; we report the epidemiological characteristics of HICP. <b>Materials & methods:</b> In this cross-sectional study, we included a random sample of adult individuals who had cell phones. <b>Results & conclusion:</b> The weighted prevalence of HICP was 9.0%: 12.3% for women and 5.6% for men (p = 0.001). HICP was more frequently localized in the lower back and affected the economically active population. Nonsteroidal anti-inflammatory drugs were more commonly used; however, 61% of patients indicated that the effectiveness of their management was low. Overall, HICP had a negative impact on daily life activities. The effectiveness of the current treatment was low and should include an integrated approach.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-12-07DOI: 10.2217/pmt-2023-0076
Barrie L Phillips, Matthew Cl Phillips
Although the pathogenesis of migraine is not fully understood, accumulating evidence indicates migraine may be driven by impaired brain energy metabolism in the context of pathologically high levels of adenosine. Considerable evidence indicates that aminophylline, an adenosine receptor antagonist, can provide strong therapeutic relief in pain, particularly post-dural headache. Moreover, direct observations from a previously published observational case series have demonstrated a strong therapeutic impact of low-dose aminophylline in patients with severe, unremitting migraine attacks. Although higher doses of aminophylline are associated with an unfavourable adverse effect profile, low doses of aminophylline are associated with minimal adverse effects. Despite this promise, double-blinded randomized trials will be needed to determine the true therapeutic efficacy of low-dose aminophylline in migraine.
{"title":"Aminophylline in pain and migraine.","authors":"Barrie L Phillips, Matthew Cl Phillips","doi":"10.2217/pmt-2023-0076","DOIUrl":"10.2217/pmt-2023-0076","url":null,"abstract":"<p><p>Although the pathogenesis of migraine is not fully understood, accumulating evidence indicates migraine may be driven by impaired brain energy metabolism in the context of pathologically high levels of adenosine. Considerable evidence indicates that aminophylline, an adenosine receptor antagonist, can provide strong therapeutic relief in pain, particularly post-dural headache. Moreover, direct observations from a previously published observational case series have demonstrated a strong therapeutic impact of low-dose aminophylline in patients with severe, unremitting migraine attacks. Although higher doses of aminophylline are associated with an unfavourable adverse effect profile, low doses of aminophylline are associated with minimal adverse effects. Despite this promise, double-blinded randomized trials will be needed to determine the true therapeutic efficacy of low-dose aminophylline in migraine.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2024-01-08DOI: 10.2217/pmt-2023-0112
Diego M Martinez, Billy K Huh, Saba Javed
Trigeminal neuralgia represents a form of chronic facial pain that is characterized by its incapacitating nature. The current therapeutic approaches encompass pharmacological agents with carbamazepine or non-pharmacologic options including utilization of percutaneous rhizotomy, Gamma knife radiosurgery or microvascular decompression may be indicated in certain cases. While the interventions may be effective, medications have negative side effects and procedures are invasive which can pose challenges for patients with various comorbidities. High-intensity laser therapy (HILT) has demonstrated safety and efficacy for many types of chronic pain such as musculoskeletal, autoimmune and neuropathic. Herein, we demonstrate the benefits of HILT therapy in the management of trigeminal neuralgia in a 72 year-old patient with a complex history of facial surgery and radiation who had failed pharmacological treatments and denied any invasive procedures.
{"title":"Case report: use of high-intensity laser therapy for treatment of trigeminal neuralgia.","authors":"Diego M Martinez, Billy K Huh, Saba Javed","doi":"10.2217/pmt-2023-0112","DOIUrl":"10.2217/pmt-2023-0112","url":null,"abstract":"<p><p>Trigeminal neuralgia represents a form of chronic facial pain that is characterized by its incapacitating nature. The current therapeutic approaches encompass pharmacological agents with carbamazepine or non-pharmacologic options including utilization of percutaneous rhizotomy, Gamma knife radiosurgery or microvascular decompression may be indicated in certain cases. While the interventions may be effective, medications have negative side effects and procedures are invasive which can pose challenges for patients with various comorbidities. High-intensity laser therapy (HILT) has demonstrated safety and efficacy for many types of chronic pain such as musculoskeletal, autoimmune and neuropathic. Herein, we demonstrate the benefits of HILT therapy in the management of trigeminal neuralgia in a 72 year-old patient with a complex history of facial surgery and radiation who had failed pharmacological treatments and denied any invasive procedures.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139378168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01Epub Date: 2023-12-06DOI: 10.2217/pmt-2023-0062
Afrin Sagir, Melissa Murphy, Richard Teames, Doug Calenda
Erector spinae plane block (ESPB) is an inter-fascial plane block that provides multi-dermatomal analgesia for treatment of acute pain and chronic neuropathic pain in the trunk. This retrospective case series describes a novel method of treating acute postoperative pain after spinal cord stimulation implant with erector spinae plane block using liposomal bupivacaine. Bilateral erector spinae plane block was administered at L1-L2 intervertebral level in 18 cases prior to performing spinal cord stimulation implant at one interspace above. This study reveals that the block provides effective analgesia as evidenced by low pain scores and less opioid consumption after surgery.
{"title":"Enhancing post-operative analgesia following spinal cord stimulation implant: a comprehensive evaluation of the effectiveness of erector spinae plane block utilizing liposomal bupivacaine.","authors":"Afrin Sagir, Melissa Murphy, Richard Teames, Doug Calenda","doi":"10.2217/pmt-2023-0062","DOIUrl":"10.2217/pmt-2023-0062","url":null,"abstract":"<p><p>Erector spinae plane block (ESPB) is an inter-fascial plane block that provides multi-dermatomal analgesia for treatment of acute pain and chronic neuropathic pain in the trunk. This retrospective case series describes a novel method of treating acute postoperative pain after spinal cord stimulation implant with erector spinae plane block using liposomal bupivacaine. Bilateral erector spinae plane block was administered at L1-L2 intervertebral level in 18 cases prior to performing spinal cord stimulation implant at one interspace above. This study reveals that the block provides effective analgesia as evidenced by low pain scores and less opioid consumption after surgery.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138488240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}